Fig. 1: High expression of lncRNA DLEU2 is associated with breast cancer patients’ treatment outcomes. | Cell Death Discovery

Fig. 1: High expression of lncRNA DLEU2 is associated with breast cancer patients’ treatment outcomes.

From: Long noncoding RNA DLEU2 and ROR1 pathway induces epithelial-to-mesenchymal transition and cancer stem cells in breast cancer

Fig. 1

A (Boxplot), and B (Scatter diagram). The differential expression of lncRNA DLEU2 in breast tumors and normal tissues (The data were retrieved and analyzed from the GEPIA database). C LncRNA DLEU2 expression of pre-and-post-treatment breast cancer patients (n = 38) treated with four cycles of epirubicin combined with chemotherapy (Wilcoxon test, P = 0.00083). D The lncRNA DLUE2 mRNA expression in different molecular subtypes and different responses to chemotherapy including complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) in breast cancer (n = 38) patients. Patients were treated with neoadjuvant chemotherapy as described in the materials and methods section. E Relative lncRNA DLEU2 expression levels in response to chemotherapy (**P < 0.01). F Violin plot showing the expression levels of lncRNA DLEU2 in breast cancer patients with pCR (pathological complete response) compared with those of non-pCR patient groups (**P < 0.01). G LncRNA DLEU2 expression of pre-and-post-treatment breast cancer patients treated with four cycles of epirubicin combined with chemotherapy (Wilcoxon test, P = 0.022). GSE84755, Kimbung et al. [3]. H The Kaplan–Meier disease-free survival curve of advanced breast cancer patients classified as low- and -high lncRNA-DLEU2 groups based on the median expression level of lncRNA DLEU2. I The association between lncRNA DLEU2 expression and the clinical parameters of breast cancer patients by multivariate analysis.

Back to article page